Ryszard Kole

10.8k total citations · 3 hit papers
107 papers, 8.3k citations indexed

About

Ryszard Kole is a scholar working on Molecular Biology, Genetics and Genetics. According to data from OpenAlex, Ryszard Kole has authored 107 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Molecular Biology, 17 papers in Genetics and 13 papers in Genetics. Recurrent topics in Ryszard Kole's work include RNA Research and Splicing (43 papers), RNA Interference and Gene Delivery (41 papers) and RNA and protein synthesis mechanisms (36 papers). Ryszard Kole is often cited by papers focused on RNA Research and Splicing (43 papers), RNA Interference and Gene Delivery (41 papers) and RNA and protein synthesis mechanisms (36 papers). Ryszard Kole collaborates with scholars based in United States, Thailand and Switzerland. Ryszard Kole's co-authors include Sidney Altman, Peter Sazani, Adrian R. Krainer, Zbigniew Domiński, Halina Sierakowska, Danielle R. Mercatante, Paul J. Furdon, R. L. Juliano, Natee Jearawiriyapaisarn and Benjamin C. Stark and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Ryszard Kole

106 papers receiving 8.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

RNA therapeutics: beyond RNA interference and antisense oligonucleotides

2012 916 citations Ryszard Kole, Adrian R. Krainer et al. Nature Reviews Drug Discovery profile →
Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

2011 656 citations Sebahattin Çirak, Virginia Arechavala‐Gomeza et al. The Lancet profile →
Ribonuclease P: an enzyme with an essential RNA component.

1978 227 citations Benjamin C. Stark, Ryszard Kole et al. profile →

Peers

Ryszard Kole

MB

GENET

CCM

CR

Andréa Pavirani France

John Choi United States

Alan M. Gewirtz United States

Rik Gijsbers Belgium

Maarten Fornerod Netherlands

Megerditch Kiledjian United States

Elio F. Vanin United States

Dimitri Scholz Germany

Kamel Mamchaoui France

Robert A. Lazarus United States

Andréa Pavirani France

Ryszard Kole

4.1k ×0.5

MB

3.6k ×2.8

GENET

580 ×0.6

GENET

344 ×0.7

CCM

341 ×0.7

CR

Citations per year, relative to Ryszard Kole Ryszard Kole (= 1×) peers Andréa Pavirani

Countries citing papers authored by Ryszard Kole

Since Specialization

Citations

This map shows the geographic impact of Ryszard Kole's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryszard Kole with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryszard Kole more than expected).

Fields of papers citing papers by Ryszard Kole

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryszard Kole. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryszard Kole. The network helps show where Ryszard Kole may publish in the future.

Co-authorship network of co-authors of Ryszard Kole

This figure shows the co-authorship network connecting the top 25 collaborators of Ryszard Kole. A scholar is included among the top collaborators of Ryszard Kole based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryszard Kole. Ryszard Kole is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Dang, Yan L., Catharina van Heusden, Yang Wang, et al.. (2021). Enhanced delivery of peptide-morpholino oligonucleotides with a small molecule to correct splicing defects in the lung. Nucleic Acids Research. 49(11). 6100–6113. 14 indexed citations

2.

Jearawiriyapaisarn, Natee, et al.. (2020). Engineered U7 Small Nuclear RNA Restores Correct β-Globin Pre-mRNA Splicing in Mouse β ^IVS2-654 -Thalassemic Erythroid Progenitor Cells. Human Gene Therapy. 32(9-10). 473–480. 6 indexed citations

3.

Kole, Ryszard, Adrian R. Krainer, & Sidney Altman. (2012). RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nature Reviews Drug Discovery. 11(2). 125–140. 916 indexed citations breakdown →

4.

Fletcher, Sue, C. Adkin, Brenda Wong, et al.. (2012). Targeted Exon Skipping to Address “Leaky” Mutations in the Dystrophin Gene. Molecular Therapy — Nucleic Acids. 1. e48–e48. 17 indexed citations

5.

Bauman, John A. & Ryszard Kole. (2011). Modulation of RNA splicing as a potential treatment for cancer. PubMed. 2(3). 125–128. 25 indexed citations

6.

Adams, A.M., et al.. (2011). Mismatched single stranded antisense oligonucleotides can induce efficient dystrophin splice switching. BMC Medical Genetics. 12(1). 141–141. 10 indexed citations

7.

Çirak, Sebahattin, Virginia Arechavala‐Gomeza, Michela Guglieri, et al.. (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. The Lancet. 378(9791). 595–605. 656 indexed citations breakdown →

8.

Mair, Lamar O., et al.. (2009). Size-Uniform 200 nm Particles: Fabrication and Application to Magnetofection. Journal of Biomedical Nanotechnology. 5(2). 182–191. 13 indexed citations

9.

Bauman, John A., Natee Jearawiriyapaisarn, & Ryszard Kole. (2009). Therapeutic Potential of Splice-Switching Oligonucleotides. Oligonucleotides. 19(1). 1–13. 122 indexed citations

10.

Kole, Ryszard, et al.. (2007). Switching on transgene expression by correcting aberrant splicing using multi‐targeting steric‐blocking oligonucleotides. The Journal of Gene Medicine. 9(6). 498–510. 20 indexed citations

11.

Kole, Ryszard, et al.. (2004). Modification of Alternative Splicing by Antisense Therapeutics. Oligonucleotides. 14(1). 65–74. 39 indexed citations

12.

Sazani, Peter & Ryszard Kole. (2003). Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. Journal of Clinical Investigation. 112(4). 481–486. 168 indexed citations

13.

Sazani, Peter & Ryszard Kole. (2003). Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. Journal of Clinical Investigation. 112(4). 481–486. 165 indexed citations

14.

Sierakowska, Halina, Sudhir Agrawal, & Ryszard Kole. (2003). Antisense Oligonucleotides as Modulators of Pre-mRNA Splicing. Humana Press eBooks. 133. 223–234. 9 indexed citations

15.

Mercatante, Danielle R. & Ryszard Kole. (2002). Control of alternative splicing by antisense oligonucleotides as a potential chemotherapy: effects on gene expression. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1587(2-3). 126–132. 37 indexed citations

16.

Suwanmanee, Thipparat, Halina Sierakowska, Giuseppina Lacerra, et al.. (2002). Restoration of Human β-Globin Gene Expression in Murine and Human IVS2–654 Thalassemic Erythroid Cells by Free Uptake of Antisense Oligonucleotides. Molecular Pharmacology. 62(3). 545–553. 54 indexed citations

17.

Mercatante, Danielle R., et al.. (2000). Restoration of Correct Splicing of Thalassemic β-Globin Pre-mRNA by Modified U1 snRNAs. Journal of Biological Chemistry. 275(46). 35914–35919. 30 indexed citations

18.

Mercatante, Danielle R. & Ryszard Kole. (2000). Modification of alternative splicing pathways as a potential approach to chemotherapy. Pharmacology & Therapeutics. 85(3). 237–243. 59 indexed citations

19.

Friedman, Kenneth J., Jolanta Kole, Jonathan Cohn, et al.. (1999). Correction of Aberrant Splicing of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene by Antisense Oligonucleotides. Journal of Biological Chemistry. 274(51). 36193–36199. 116 indexed citations

20.

Altman, Sidney, Emma Jean Bowman, Richard L. Garber, et al.. (1980). Aspects of RNase P Structure and Function. Cold Spring Harbor Monograph Archive. 71–82. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact